Seek Returns

MEDP vs. PCVX: Medpace vs. Vaxcyte Stock Comparison

How do Medpace (MEDP) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and Vaxcyte (PCVX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while PCVX is classified in Biotechnology.

Company profile comparison for Medpace (MEDP) and Vaxcyte (PCVX)
Profile ItemMEDPPCVX
NameMedpace Holdings, Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization18.27 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateAugust 11, 2016June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

MEDP
PCVX
GSPC
Loading price history…
Medpace (MEDP) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Medpace (MEDP) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Medpace (MEDP) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
Total Return (1Y)13.29%59.00%
Total Return (3Y, Annualized)35.26%11.29%
Total Return (5Y, Annualized)24.49%21.60%

Risk Profile

Drawdown History

MEDP
PCVX
GSPC
Loading price history…
Medpace (MEDP) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Medpace (MEDP) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
Volatility (1Y, Annualized)44.16%56.01%
Beta (5Y)1.101.26
Max Drawdown (5Y)-42.87%-76.22%
Avg. Volume (3M)258.39K2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
MEDP and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
Sharpe Ratio (1Y)0.200.98
Sortino Ratio (1Y)0.261.76

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP
117.88%
Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP
18.24%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Medpace (MEDP) at 23.12% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max
83.12%
MEDP
23.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
ROE (TTM)117.88%-42.68%
ROA (TTM)18.71%-24.98%
Net Margin (TTM)18.24%0.00%
Operating Margin (TTM)23.12%0.00%
Gross Margin (TTM)72.24%0.00%

Growth

Revenue Growth

Only one side can be read here: Medpace (MEDP) reports revenue growth of 19.97%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
Revenue Growth (YoY)19.97%--
Revenue Growth (3Y CAGR)20.12%--
EPS Growth (YoY)20.98%--
EPS Growth (3Y CAGR)28.04%--

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MEDP
0.83
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Medpace (MEDP) at 0.29 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max
1.42
Q3
0.65
MEDP
0.29
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
Current Ratio (MRQ)0.834.56
Debt / Equity (MRQ)0.290.09
Net Debt / EBITDA-0.84--

Dividends

Dividend Yield (TTM)

Neither Medpace (MEDP) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Medpace (MEDP) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max
85.34
Q3
43.46
MEDP
36.26
Median
26.69
Q1
13.30
Min
0.07

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): PCVX does not report P/E ratio, so it has no value marker; MEDP is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Medpace (MEDP), whose P/S ratio of 6.44 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max
58.18
Q3
25.77
Median
7.30
MEDP
6.44
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; MEDP is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Vaxcyte (PCVX) at 3.83 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP
31.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Medpace (MEDP) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and Vaxcyte (PCVX)
MetricMEDPPCVX
P/E Ratio (TTM)36.26--
P/S Ratio (TTM)6.44--
P/B Ratio (MRQ)31.233.83
Free Cash Flow Yield (TTM)2.72%-5.24%